Ymmunobio and EVIIVE announce collaboration to develop advanced liquid biopsy for detecting NPTXR in cancer patients
In the pursuit of scientific advancement, the journey from theoretical research to tangible solutions is often fraught with challenges.
Published by
FirstWord Pharma
Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in the field of precision medicine, aiming to enhance the accuracy and efficacy of disease detection and patient monitoring.
The newly developed liquid biopsy will utilize the unique properties of EVs to provide a non-invasive and highly precise diagnostic tool. Ymmunobio plans to leverage this cutting-edge technology to test patients for NPTXR. This will help determine their eligibility for treatment with their YB-800 platform drugs, ensuring more personalized and effective treatment strategies.
Dr. Peter Schiemann, Ymmunobio CEO and Chair of the Board says: “This collaboration with EVIIVE underscores both companies’ commitment to innovation and improving patient outcomes through advanced diagnostic and therapeutic solutions. We are proud to having found a great partner with such an innovative diagnostic solution. Together, Ymmunobio and EVIIVE are pioneering advances in diagnostics and oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.”
Dr. Kevin Yim, EVIIVE Co-founder and CEO says: "We are excited to collaborate with Ymmunobio to co-develop a companion diagnostic assay that leverages our unique single EV biomarker discovery approach. Our technology focuses on intercepting the crosstalk between immune cells and tumor cells which aligns perfectly with YB-800’s unique therapeutic approach. Together, we can bring the next-generation diagnostic assay to cancer patients for more precise and reliable treatment guidance.”
